Oncosil Medical Limited is an Australia-based biotechnology development company focused on the radiotherapy technology for the treatment of cancer. The Company’s core technology includes the application of radioactive phosphorus (P32) to patients to control tumor growth. The Company along with a German radio pharmaceutical and nuclear medicine company, Eckert & Ziegler, is engaged in the manufacture of OncoSil. Its lead product OncoSil is a class III implantable nuclear medical device that emits radiation locally into a tumor and is in late stage clinical research. OncoSil is a bio-silica P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment to control tumor growth. OncoSil device delivers localized beta radiation and is used in other solid tumors outside of pancreatic cancer. The Company’s subsidiaries include Enigma Therapeutics Limited, United Kingdom; OncoSil Medical Germany GmbH, Germany, and OncoSil Medical US Inc., United States.